Ashland Inc. ASH

The business

Ashland sells specialty additives and ingredients into pharma, personal care, food, coatings, and industrial markets through four segments. Life Sciences (≈30% of FY25 revenue, pharma-grade cellulosic polymers used as tablet binders, controlled-release matrices, and coatings) and Personal Care (≈28%, naturally-derived rheology modifiers, conditioning polymers, and biodegradable surfactants) are the franchise. Specialty Additives (≈26%, coatings rheology modifiers, energy and construction additives, ceramic materials) is the cyclical middle. Intermediates and Solvents (≈16%, 1,4-butanediol and N-methylpyrrolidone, commodity-adjacent chemistry serving electronics and industrial end markets) is the problem. The engine is Life Sciences plus Personal Care: combined ≈58% of revenue but closer to 75-80% of segment EBITDA at mid-teens to low-20s margins, while Intermediates has bled cash through the 2024-2025 BDO oversupply cycle driven by Chinese capacity additions.

The qualitative fact the financials don't show is that the FY25 GAAP loss is almost entirely a non-cash goodwill and intangibles impairment tied to Intermediates and to legacy acquisitions (Pharmachem, ISP). Cash flow tells a different story: operating cash flow ran ≈$407M and free cash flow ≈$335M on a ≈$1.82B revenue base, a 22% OCF margin and 18% FCF margin that any specialty chemicals investor would underwrite as healthy. The market knows this, which is why the stock is up about 40% off the April 2025 low and priced near 52-week highs while the headline EPS is negative $18. The setup is a classic kitchen-sink quarter followed by a multi-quarter portfolio reshape.